Skip to main content
Clinical Trials/NCT03577808
NCT03577808
Unknown
Not Applicable

Validation of Organoids Potential Use as a Companion Diagnostic in Predicting Neoadjuvant Chemoradiation Sensitivity in Locally Advanced Rectal Cancer

Zhen Zhang1 site in 1 country80 target enrollmentStarted: August 17, 2018Last updated:

Overview

Phase
Not Applicable
Sponsor
Zhen Zhang
Enrollment
80
Locations
1
Primary Endpoint
Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.

Overview

Brief Summary

Patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids model from the pre-treatment biopsies and expose organoids to irradiation and the same chemotherapy drugs. The sensitivity of irradiation and chemotherapy drugs will be tested in the organoids model. Here, the investigators will launch the observational clinical trial to validate whether the organoids could predict the clinical outcome in locally advanced rectal cancer patients underwent neoadjuvant chemoradiation.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • pathological confirmed adenocarcinoma
  • clinical stage T3-4 and/or N+
  • the distance from anal verge less than 12 cm
  • without distance metastases
  • KPS \>=70
  • without previous anti-cancer therapy
  • sign the inform consent

Exclusion Criteria

  • pregnancy or breast-feeding women
  • serious medical illness
  • baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/L, Hb≥90g/L, PLT≥100×10\^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN

Outcomes

Primary Outcomes

Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.

Time Frame: 2018.08-2020.11

The investigators will culture rectal cancer organoids and treat with irradiation and the same chemotherapy drugs as the corresponding patient. The number and size of alive organoids will be observed after treatment. The correlation of organoids sensitivity and patient response will be evaluated.

Secondary Outcomes

  • Response of the rectal cancer patients to neoadjuvant chemoradiation.(2018.08-2020.11)

Investigators

Sponsor
Zhen Zhang
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Zhen Zhang

Professor Zhang

Fudan University

Study Sites (1)

Loading locations...

Similar Trials